Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 949 - 956
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
Published online 06 January 2020
  1. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13: 473–486. [Google Scholar]
  2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 ; 12: 252–264. [Google Scholar]
  3. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018 29 (suppl 4): iv264–i6. [CrossRef] [PubMed] [Google Scholar]
  4. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016 ; 60: 12–25. [CrossRef] [PubMed] [Google Scholar]
  5. Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017 ; 19: 3. [CrossRef] [PubMed] [Google Scholar]
  6. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017 ; 13: 195–207. [CrossRef] [PubMed] [Google Scholar]
  7. Sibaud V, Boulinguez S, Pagès C, et al. Dermatologic toxicities of immune checkpoint inhibitors. Ann Dermatol Venereol 2018 ; 145: 313–330. [CrossRef] [PubMed] [Google Scholar]
  8. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: A new type of inflammatory bowel disease?. ACG Case Rep J 2017 ; 4: e112. [Google Scholar]
  9. Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017 ; 28: 2860–2865. [CrossRef] [PubMed] [Google Scholar]
  10. Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: Anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis 2017 ; 11: 1238–1246. [CrossRef] [PubMed] [Google Scholar]
  11. Gentile NM, D’Souza A, Fujii LL, et al. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013 ; 88: 414–417. [CrossRef] [PubMed] [Google Scholar]
  12. De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018 ; 68: 1181–1190. [CrossRef] [PubMed] [Google Scholar]
  13. Su Q, Zhang X-C, Zhang C-G, et al. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: Systematic assessment with meta-analysis. J Immunol Res 2018 ; 2018: 1027323. [PubMed] [Google Scholar]
  14. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018 ; 378: 158–168. [Google Scholar]
  15. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018 ; 67: 1471–1480. [CrossRef] [PubMed] [Google Scholar]
  16. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017 ; 35: 709–717. [CrossRef] [PubMed] [Google Scholar]
  17. Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 2017 ; 23: 620–624. [CrossRef] [PubMed] [Google Scholar]
  18. Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 2017 ; 2: 709–718. [Google Scholar]
  19. Moslehi JJ, Salem J-E, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018 ; 391: 933. [Google Scholar]
  20. Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer 2017 ; 41: 100–110. [CrossRef] [PubMed] [Google Scholar]
  21. Bitton K, Michot J-M, Barreau E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol 2019 ; 202: 109–117. [CrossRef] [PubMed] [Google Scholar]
  22. Delanoy N, Michot J-M, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019 ; 6: e48–e57. [CrossRef] [PubMed] [Google Scholar]
  23. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28: 368–376. [CrossRef] [PubMed] [Google Scholar]
  24. Johnson DB, Khushalani NI, Puzanov I, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J Clin Oncol 2017 ; 33: suppl 9019. [Google Scholar]
  25. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016 ; 375: 143–153. [Google Scholar]
  26. Lipson EJ, Bagnasco SM, Moore J, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016 ; 374: 896–898. [Google Scholar]
  27. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007 ; 179: 5204–5210. [CrossRef] [PubMed] [Google Scholar]
  28. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019 ; 7: 106. [Google Scholar]
  29. Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol 2019 ; 5: 1049–1054. [CrossRef] [PubMed] [Google Scholar]
  30. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016 ; 27: 559–574. [CrossRef] [PubMed] [Google Scholar]
  31. Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 2017; 109. doi: 10.1093/jnci/djw260. [Google Scholar]
  32. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 2017 ; 5: 95. [Google Scholar]
  33. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018 ; 36: 1714–1768. [CrossRef] [PubMed] [Google Scholar]
  34. Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine society guidance on endocrine side-effects of immunotherapy. Endocr Relat Cancer 2018 Oct 1; pii: ERC-18-0320.R1. [Google Scholar]
  35. Gauci M-L, Baroudjian B, Zeboulon C, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed?. J Hepatol 2018 ; 69: 548–550. [CrossRef] [PubMed] [Google Scholar]
  36. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2017 ; 77: 393–398. [CrossRef] [PubMed] [Google Scholar]
  37. Roberts J, Smylie M, Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 2019 ; 38: 1513–1519. [Google Scholar]
  38. Ford M, Sahbudin I, Filer A, et al. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology 2018 ; 57: 2244–2246. [CrossRef] [PubMed] [Google Scholar]
  39. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016 ; 2: 1346–1353. [CrossRef] [PubMed] [Google Scholar]
  40. Beardslee T, Draper A, Kudchadkar R. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. J Oncol Pharm Pract 2019 ; 25: 1275–1281. [CrossRef] [PubMed] [Google Scholar]
  41. Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019 ; 25: 551–557. [CrossRef] [PubMed] [Google Scholar]
  42. Khan U, Ali F, Khurram MS, et al. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 2017 ; 5: 15. [Google Scholar]
  43. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014 ; 15: 69–77. [CrossRef] [PubMed] [Google Scholar]
  44. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017 ; 66: 581–592. [CrossRef] [PubMed] [Google Scholar]
  45. Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017 ; 376: 1989–1991. [Google Scholar]
  46. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017 ; 35: 3807–3814. [CrossRef] [PubMed] [Google Scholar]
  47. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009 ; 15: 5591–5598. [CrossRef] [PubMed] [Google Scholar]
  48. Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. Arthritis Rheum 2019: 10.1002/art.41068. [Google Scholar]
  49. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018 ; 36: 2872–2878. [CrossRef] [PubMed] [Google Scholar]
  50. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018 ; 4: 374–378. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.